The shadow of generic challenges has repeatedly loomed above copyright’s iconic drug, Sildenafil, raising questions about the future of similar drug portfolios. While initial times saw substantial profits, the exclusivity lapse has allowed the path for cheaper copies, possibly diminishing profitability and creating a real hazard for investors see